BioRestorative Therapies Announces Completion of BRTX-100 Phase 2 Manufacturing, Highlighting Integrated Regenerative Biologics PlatformGlobeNewsWire • 06/25/26
BioRestorative Therapies Strengthens Leadership with Appointment of Healthcare Executive Zachary Smith as Vice President of Biocosmeceuticals Division to Accelerate Commercial Expansion and Strategic GrowthGlobeNewsWire • 06/18/26
Kaos Capital Announces Acquisition of 4.9% Stake in BioRestorative Therapies (NASDAQ: BRTX)PRNewsWire • 05/27/26
BioRestorative Completes Phase 2 Dosing of BRTX-100, Advancing Lead Regenerative Spine Program Toward 2027 Topline DataGlobeNewsWire • 05/26/26
Biorestorative Therapies, Inc. (BRTX) Reports Q1 Loss, Misses Revenue EstimatesZacks Investment Research • 05/15/26
BioRestorative Therapies Presents New Preclinical Data at ISCT 2026 Highlighting Source-Specific Exosome Functionality and Commercial Applications in BioCosmeceuticalsGlobeNewsWire • 05/13/26
BioRestorative Therapies Reports Expanded Phase 2 Blinded Dataset for BRTX-100 Showing Sustained Pain and Functional Improvements in Chronic Lumbar Disc DiseaseGlobeNewsWire • 05/07/26
BioRestorative Therapies to Present New Data at ISCT 2026 Highlighting Its Ongoing Phase 2 Clinical Trial in Chronic Lumbar Disease and Its BioCosmeceutical PlatformGlobeNewsWire • 04/30/26
Here's Why Biorestorative Therapies (BRTX) Looks Ripe for Bottom FishingZacks Investment Research • 04/27/26
BioRestorative Therapies Announces Strategic Partnership with Global Dermatology Leader Dr. David J. Goldberg to Lead Clinical Evaluation and Seek Multi-Channel Adoption of Its Regenerative BioCosmeceutical PlatformGlobeNewsWire • 04/21/26
BioRestorative Therapies Announces Strategic Collaboration with 203 Creates to Build and Commercialize Biocosmeceutical PlatformGlobeNewsWire • 04/07/26
BioRestorative Therapies Reports Positive Phase 2 Blinded Data for BRTX-100 Demonstrating Meaningful Improvements in Pain and Function in Chronic Lumbar Disc DiseaseGlobeNewsWire • 03/30/26
Biorestorative Therapies, Inc. (BRTX) Reports Q4 Loss, Lags Revenue EstimatesZacks Investment Research • 03/26/26
BioRestorative Therapies to Present Positive Phase 2 Blinded Data for BRTX-100 Demonstrating Meaningful Improvements in Pain and Function in Chronic Lumbar Disc DiseaseGlobeNewsWire • 03/19/26
BioRestorative Therapies, Inc. to Participate in the Be+Well Beauty and Wellness Show in New York City, March 8-10, 2026GlobeNewsWire • 03/05/26
BioRestorative Expands Global Protection for ThermoStem®, a Potentially Longer-Lasting and Safer Cell-Based Alternative to GLP-1 DrugsGlobeNewsWire • 02/24/26
Biorestorative Therapies, Inc. (BRTX) Reports Q3 Loss, Lags Revenue EstimatesZacks Investment Research • 11/13/25
BioRestorative Therapies to Report Third Quarter 2025 Financial Results and Host Conference Call on November 12, 2025GlobeNewsWire • 11/05/25
BioRestorative Awarded Notice of Allowance for Japanese Patent – Expands Protection for Potential Cell-Based Alternative to Multi-Billion Dollar GLP-1 Drug MarketGlobeNewsWire • 10/27/25